Skip to main content
Contact Us
Subscribe
E-Edition
32°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bioatla Inc
(NQ:
BCAB
)
1.680
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bioatla Inc
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
September 23, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
December 05, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
November 30, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
November 28, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 07, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
October 12, 2023
Award recognizes Dr. Short’s contribution to science innovation
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
October 10, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in Upcoming Investor Conferences in August
August 03, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 01, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
July 25, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
June 26, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 11, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the JMP Securities Life Sciences Conference
May 08, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
May 04, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
March 23, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
March 16, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Announces Change in Executive Leadership
February 27, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
February 23, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
January 10, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 22, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the Jefferies London Healthcare Conference
November 08, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
November 04, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 03, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
October 27, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
August 02, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.